Abu Dhabi Stem Cells Center

What Abu Dhabi Stem Cells Center does

Abu Dhabi Stem Cells Center (ADSCC) is a for-profit, specialized healthcare facility founded in March 2019 and headquartered in Abu Dhabi, UAE, operating as a wholly-owned subsidiary of PureHealth Holding PJSC (publicly listed on the Abu Dhabi Securities Exchange). It delivers an integrated portfolio of advanced cellular therapy and regenerative medicine services built around a proprietary hematopoietic stem cell transplant program called AD-BMT©, an in-house CAR-T cell manufacturing capability (the first in the UAE, including Middle East-first use in lupus), a Tumor-Infiltrating Lymphocytes (TILs) program, virus-free clinical-grade induced pluripotent stem cell (iPSC) generation (first in the Middle East), and CRISPR-Cas9-based gene therapy administration via Vertex/AstraZeneca's CASGEVY for sickle cell disease and beta thalassemia. Supporting infrastructure includes GMP-compliant cell processing labs, a Helios Mass Cytometer, and the AI-augmented FLAIRstar MRI tool (co-developed with NYU Abu Dhabi) for multiple sclerosis diagnostics.

Its clinical service menu spans hematology and BMT, CAR-T and TILs oncology immunotherapy, neurology (including the PHOMS Extracorporeal Photopheresis trial), diabetes and kidney disease research, fertility preservation, cord blood and adult stem cell banking, and an emerging longevity, wellness, and preventive-care line (NAD+ therapy, hyperbaric oxygen, anti-aging programs, executive screening, digital detox for children). Patient acquisition combines physician referrals, an international patient program (treating cases from Gaza and Pakistan), and partnerships with Burjeel Medical City, Sheikh Shakhbout Medical City, Cleveland Clinic Abu Dhabi, SEHA, and Emirates Red Crescent for underprivileged patient access. Revenue is generated through clinical healthcare services on a fee-for-treatment basis, with pricing not publicly disclosed; demand is anchored on rare and complex conditions (blood cancers, sickle cell, thalassemia, MS, rare pediatric genetic disorders) plus premium wellness services.

ADSCC's economic position rests on multiple high-barrier credentials: FACT accreditation for cellular therapy (first in UAE, one of only two in the Middle East), AABB accreditation for hematopoietic progenitor cell collection (first in UAE), and Centre of Excellence designation by the Department of Health – Abu Dhabi. It is led by Prof. Yendry Ventura (CEO) and Dr. Fatima Al Kaabi (Executive Director of AD-BMT©) and runs an annual Bone Marrow Transplant & Cellular Therapy Congress convening 2,300+ global experts, which reinforces referral networks and thought leadership. Operational scale is modest but accelerating: 51–100 employees, 240 total BMTs since 2022 (with 113 performed in 2025) and 26 CAR-T therapies delivered at an 80% survival rate.

Name

Abu Dhabi Stem Cells Center

Legal name

ABU DHABI STEM CELLS CENTER – SOLE PROPRIETORSHIP L.L.C.

Website

https://adscc.ae

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

51–100 employees

Short description

Abu Dhabi Stem Cells Center (ADSCC) is a UAE-based subsidiary of PureHealth that delivers cell therapy, regenerative medicine, bone marrow transplantation, CAR-T, gene therapy, and longevity services to hematology, oncology, neurology, and wellness patients across the Middle East.

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Health Care and Social Assistance (62)

SIC

Services-Health Services (8000), Services-General Medical & Surgical Hospitals, Nec (8062)

akta.pro primary industry

Stem Cell–Based Regenerative Therapies (HLAAAGAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Developers (Autologous) (HLAAABAA), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

Keywords

• Cellular therapy services
• Stem cell banking
• Regenerative medicine
• Bone marrow transplant
• Gene therapy

Headquarters

HQ city

Abu Dhabi

HQ country

United Arab Emirates

HQ region

Middle East

Offices3 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Healthcare Services: Revenue generated from providing medical treatments and procedures including bone marrow transplants, cellular therapies, CAR-T therapy, regenerative medicine procedures, and other clinical services to patients

Go-to-market motion1 record

Distribution channels6 records

Marketing channels5 records

Core offering

Abu Dhabi Stem Cells Center is a specialized healthcare center that provides advanced cell therapy and regenerative medicine services, including autologous and allogeneic bone marrow transplantation, CAR-T cell therapy, gene therapy, and stem cell banking. The center operates clinical programs for hematological diseases, diabetes, kidney diseases, and multiple sclerosis, alongside stem cell banking and wellness/longevity services.

Product overview

Abu Dhabi Stem Cells Center operates as a specialized healthcare center offering an integrated ecosystem of cellular therapy and regenerative medicine services. The core clinical programs include AD-BMT© (bone marrow transplantation), CAR-T Cell Engineering, TILs Therapy, and Regenerative Medicine. Supporting infrastructure includes cord blood/tissue banking, adult stem cell banking, and pharmacogenomics services. Wellness offerings span Anti-Aging Programs, Executive Screening, NAD+ Therapy, Hyperbaric Oxygen Therapy, and Digital Detox for Children. Advanced treatments include UAECell19 for respiratory conditions, stem cell hair therapy, fertility preservation, and ECP for MS. The center also operates dedicated clinical programs for Diabetes, Kidney Diseases, Multiple Sclerosis, and Longevity, supported by diagnostic technologies including the Middle East's only Helios Mass Cytometer and AI-powered FLAIRstar MRI analysis.

Differentiator

Problem solved

Functional benefit

Products and services

• AD-BMT© Program (Bone Marrow Transplant) Autologous and allogeneic bone marrow transplantation program for patients with hematological disorders and other conditions requiring hematopoietic stem cell transplant.
• CAR-T Cell Engineering In-house manufacturing and administration of CAR-T cell therapy for patients with hematological malignancies, the first such capability in the UAE.
• TILs Therapy Tumor-infiltrating lymphocytes (TILs) therapy for patients with solid tumor malignancies.
• Cord Blood and Tissue Banking Storage of umbilical cord blood and tissue for potential future therapeutic use, intended for newborns and their families.
• Adult Stem Cell Banking Collection and cryopreservation of adult stem cells for future therapeutic applications.
• Regenerative Medicine Regenerative medicine treatments using stem cell and cell therapy technologies for a range of degenerative conditions.
• Extracorporeal Photopheresis (ECP)

Quantifiable outcome

• 113 bone marrow transplants performed in 2025 alone; 240 total since 2022
• +4 more outcomes

Named customers9 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature9 records

Partnerships

15 partnerships are on record, tiered core and minor.

• NYU Abu DhabicoreTechnology or Integration · 18 September 2025Collaboration to develop FLAIRstar AI-powered MRI analysis technique for Multiple Sclerosis diagnosis. Partnership through LAMINATE project enabling advanced MRI research translated to clinical validation at Yas Clinic
• Yas Clinic Khalifa CitycoreStrategic or Co-development Partner · 18 September 2025Clinical partner in AI-powered MRI technique validation and primary treatment location for MS patients. Affiliated facility providing comprehensive clinical services alongside ADSCC
• Burjeel Medical CitycoreStrategic or Co-development Partner · 19 September 2024Strategic partnership to expand bone marrow transplant and cellular therapy at Burjeel Holdings' flagship facility. ADSCC extends its AD-BMT© program to Burjeel Medical City, enhancing access for adult and pediatric patients
• ART Fertility ClinicminorStrategic or Co-development Partner · 30 August 2024Collaboration for UAE's first pediatric ovarian preservation procedure for a 7-year-old leukemia patient. ART Fertility Clinic processed and preserved ovarian tissue for future fertility restoration
• Emirates Red CrescentcoreStrategic or Co-development Partner · 18 April 2024Partnership to enhance accessibility to bone marrow transplants for patients in need. ADSCC provides medical consultations to ERC-referred patients; joint fundraising initiatives to support BMT procedures for underprivileged patients
• National Multiple Sclerosis SocietycoreStrategic or Co-development Partner · 14 April 2024Awarded one of only six research grants globally to support ADSCC's PHOMS clinical trial for ECP treatment of Multiple Sclerosis. Collaboration strengthens MS research capabilities
• Kyoto University - Center for iPS Cell Research and Application (CiRA)coreStrategic or Co-development Partner · 11 January 2024Groundbreaking joint research agreement to develop innovative diabetes treatment using pancreatic beta cells derived from human induced pluripotent stem cells (iPS cells). ADSCC laboratory established at Kyoto University premises.
• Rege NephrocoreStrategic or Co-development Partner · 11 January 2024Japan-based biotech company specializing in R&D and production of renal disease therapeutics, partnering with ADSCC and Kyoto University for diabetes research using iPS cell technology
• Pontifical Academy for Life (Vatican)minorStrategic or Co-development Partner · 7 June 2023Visit from Archbishop Vincenzo Paglia to discuss extending clinical trials on ALS and MS with stem cells to UAE. Foundation Revert Onlus collaboration for neurological disorder research
• Indiana University HealthcoreStrategic or Co-development Partner · 11 May 2020MOU collaboration since 2020 for medical education, training, clinical research projects, and international publications. Provided support during development and post-launch of BMT Program, including second-opinion services
• Vertex PharmaceuticalscoreStrategic or Co-development PartnerCollaboration for CASGEVY, the CRISPR-Cas9 based gene therapy for hemoglobin disorders (sickle cell disease and beta thalassemia). ADSCC administered UAE's first gene therapy for hemoglobin disorders using this partnership.
• AstraZenecacoreStrategic or Co-development PartnerPartner in the administration of advanced gene therapies and cellular treatments including CASGEVY for hemoglobin disorders
• Department of Health - Abu DhabicoreStrategic or Co-development PartnerRegulatory oversight and support for TILs therapy program under DOH-approved observational study. Partner in advancing healthcare sector and gene therapy implementation
• Cleveland Clinic Abu DhabicoreStrategic or Co-development PartnerPartnership supporting comprehensive ecosystem for advanced cancer care in UAE. Collaboration on TILs therapy program and broader cellular therapy initiatives
• SEHAcoreStrategic or Co-development PartnerHealthcare network partner supporting ADSCC's TILs therapy program and broader cancer care ecosystem development in Abu Dhabi

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Burjeel Medical City: UAE flagship tertiary hospital under Burjeel Holdings; strategic partnership with ADSCC since Sept 2024 to extend the AD-BMT© bone marrow transplant and cellular therapy program. Operates as both a peer (specialty hospital in UAE) and a distribution channel for ADSCC's programs.
• King Faisal Specialist Hospital & Research Centre: Saudi Arabia's leading tertiary specialty hospital with a major BMT and cellular therapy program serving the Gulf region. Highly comparable to ADSCC in scope (hematology, oncology, BMT, regenerative medicine) and in serving GCC patients who would otherwise travel abroad for advanced cellular therapies.
• Cleveland Clinic Abu Dhabi: Sister asset within PureHealth's portfolio, providing multi-specialty tertiary care in Abu Dhabi and serving as a key referral source and partner for ADSCC's cellular therapy programs (including CASGEVY administration at Sheikh Shakhbout Medical City). Operates as a complementary specialty hub within the same parent group.

Regional players

• Sidra Medicine: Qatar-based specialty research hospital with strong pediatric and maternal focus and growing precision medicine capabilities. Comparable to ADSCC as a Gulf-based, research-driven specialty center backed by a national healthcare strategy.
• Sheba Medical Center (Tel HaShomer): Israel's largest hospital and a globally recognized leader in regenerative medicine, cell therapy, and clinical innovation including CAR-T and iPSC-derived therapies. Highly comparable in technology portfolio and research orientation, though serving a different patient geography.

Emerging players

• Iovance Biotherapeutics: US-based commercial leader in tumor-infiltrating lymphocyte (TIL) therapy, with FDA-approved lifileucel for melanoma. Comparable to ADSCC as a technology reference for ADSCC's newly launched UAE-first TILs program, and relevant given the global supply/demand dynamics for TIL therapy manufacturing capacity.
• Karolinska University Hospital: Sweden's leading academic hospital and a major European center for hematopoietic stem cell transplantation and cellular therapy. Comparable in scale of BMT program, research intensity, and focus on complex hematological and immunological conditions.

Broad incumbents

• Memorial Sloan Kettering Cancer Center: Co-developer of the first FDA-approved CAR-T therapies (with Novartis) and a global leader in adoptive cell therapy research. Relevant peer for ADSCC's CAR-T engineering and oncology cellular therapy programs given shared focus on autologous engineered cell therapies.
• Mayo Clinic: Global leader in BMT and CAR-T cell therapy programs with one of the largest volumes of cellular therapy procedures worldwide. Sets the clinical benchmark ADSCC aspires to for survival rates, engraftment outcomes, and multi-modality cell therapy integration.
• MD Anderson Cancer Center: Pioneer in CAR-T cell therapy and tumor-infiltrating lymphocytes (TILs) therapy for solid tumors. Comparable to ADSCC as a reference standard for the cell therapy modalities ADSCC is scaling (CAR-T, TILs) and for clinical trial design in oncology cellular therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/adsccae
• Facebookfacebook.com/adsccae
• LinkedInlinkedin.com/company/adsccae

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abu Dhabi Stem Cells Center